A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors.
A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors.
复制标题
一种新型高效甘氨酸沉淀抗血友病因子 (AHF) 浓缩物。
DOI：
10.1001/jama.1968.03140350023005
复制
发表时间：
1968
期刊：
影响因子：
--
通讯作者：
R. Wagner
中科院分区：
文献类型：
--
作者：
K. Brinkhous;E. Shanbrom;H. Roberts;W. Webster;L. Fekete;R. Wagner
一种新的、高效的、甘氨酸沉淀的抗血友病因子（AHF，因子VIII）浓缩物，从100到400倍纯化，可以在比血浆浓度高100倍的溶液中给予患者。该产品似乎是稳定的，不会立即引起不良副反应。经典血友病患者的血浆AHF水平可以通过注射器给予小体积的甘氨酸沉淀物质而正常化。手术可以在这一部分的掩护下安全地进行。2例伴有AHF循环抑制剂的典型血友病患者接受了大量高效组分治疗;抑制剂部分至完全中和，临床改善。
A new, high-potency, glycine-precipitated antihemophilic factor (AHF, factor VIII) concentrate, from 100 to 400 times purified, can be administered to patients in solutions 100 times more concentrated than plasma. The product appears to be stable and causes no immediate untoward side reactions. The plasma AHF levels of patients with classical hemophilia can be normalized with small volumes of the glycine-precipitated material given by syringe. Surgery can be performed safely under cover of this fraction. Two patients with classical hemophilia complicated by a circulating inhibitor to AHF were treated with large amounts of the high-potency fraction; partial to complete neutralization of the inhibitor occurred with clinical improvement.